Wedbush keeps Climb Bio on Best Ideas List, raises price target
Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Climb Bio Q3 EPS $(0.18) Beats $(0.20) Estimate
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
Climb Bio To Present New Clinical Data For Budoprutug In Immune Thrombocytopenia At 68th ASH Annual Meeting And Exposition
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
BTIG Reiterates Buy on Climb Bio, Maintains $32 Price Target
Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027
Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30
B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.